ASX Announcement17 January 2020PRIZMA CLINICAL TRIALS COMPLETED FORCHINA NMPA APPROVAL PROCESS
Prizma deviceclinical trials with208 patients completed across multiplehospitals in China
Major milestone in the China regulatory approval process -potentially unlocks large market entry
Trial results to be lodged with National Medical Products Administration in coming weeks
NMPAapproval will unlock GMedical’s China market entry
- Forums
- ASX - By Stock
- GMV
- Ann: Prizma Clinical Trials Completed for China Approval Process
Ann: Prizma Clinical Trials Completed for China Approval Process, page-3
-
- There are more pages in this discussion • 147 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)